The enzyme fructosamine-3-kinase (FN3K), which is known for deglycating hemoglobin20, preventing micro- and macrovascular complications in type 2 diabetes mellitus (T2DM)41, and macular degeneration by deglycating advanced glycation end products (AGEs)42, also exhibits potential oppurtunity for a therapeutic intervention. The gene discussed is FN3K; the disease is macular degeneration.